

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 6/3/2020  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation (CDG)**

ARUP test code 2002918

CDG - Reason for Referral

SEE NOTE  
RESULT: CONGENITAL DISORDERS OF GLYCOSYLATION

Mono-oligo/Di-oligo Ratio	0.02		(Ref Interval: <=0.06)
---------------------------	------	--	------------------------

A-oligo/Di-oligo Ratio	0.003		(Ref Interval: <=0.011)
------------------------	-------	--	-------------------------

Tri-sialo/Di-oligo Ratio	<b>0.06</b>	<b>H</b>	<b>(Ref Interval: &lt;=0.05)</b>
--------------------------	-------------	----------	----------------------------------

Apo CIII-1/Apo CIII-2 Ratio	2.68		(Ref Interval: <=2.91)
-----------------------------	------	--	------------------------

Apo CIII-o/Apo CIII-2 Ratio	<b>1.39</b>	<b>H</b>	<b>(Ref Interval: &lt;=0.48)</b>
-----------------------------	-------------	----------	----------------------------------

CDG - Interpretation

SEE NOTE

**H=High, L=Low, \*=Abnormal, C=Critical**

In this sample, a transferrin isoform lacking one sialic acid (tri-sialo) was present in slightly elevated amounts. In addition, apolipoprotein-CIII profile showed an increased Apo CIII-0/Apo CIII-2 Ratio. This pattern can be seen in Congenital Disorders of Glycosylation (CDG) affecting golgi homeostasis and deficiencies in subunits of the Conserved Oligomeric Golgi (COG) complex but typically with greater amounts of tri-sialo transferrin present. The elevations observed in this sample are of uncertain significance. Consider sending a repeat specimen for analysis to determine if this pattern is persistent. Please contact the Biochemical Genetics consultant on call (Tel. 1-800-533-1710) if you have any questions.

-----ADDITIONAL INFORMATION-----  
Affinity Chromatography-Mass Spectrometry (MS)  
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CDG - Reviewed By**

SEE NOTE

RESULT: Matthew J Schultz, Ph.D

Test Performed by:  
Mayo Clinic Laboratories - Rochester Main Campus  
200 First Street SW, Rochester, MN 55905  
Lab Director: William G. Morice M.D. Ph.D.; CLIA# 24D0404292

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
CDG - Reason for Referral	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Mono-oligo/Di-oligo Ratio	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
A-oligo/Di-oligo Ratio	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tri-sialo/Di-oligo Ratio	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Apo CIII-1/Apo CIII-2 Ratio	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Apo CIII-0/Apo CIII-2 Ratio	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CDG - Interpretation	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CDG - Reviewed By	23-115-138508	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at: